Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February it announced a major agreement with Quest Diagnostics, the world’s leading diagnostic information services company, which will offer Natera’s
new Panorama prenatal test. Since then, Natera has also inked agreements to offer Panorama through two more labs — Bio-Reference Laboratories and ARUP Laboratories.
We’ve always supported the Natera team because of their development and deployment of the broadest and most accurate prenatal tests. It fits right in with our belief that medicine is beginning to be transformed by companies in our target market of digital health and, specifically, personalized genetic informatics.